ERBB2/Her-2-overexpressing NSCLC implies an inferior outcome [122], as ERBB2/Her-2 amplification is known to be one of the acquired EGFR TKI resistance mechanisms [122] that can be identified by NGS-based liquid biopsies [123]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.